Ellodi Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ellodi Pharmaceuticals is a private, pre-revenue biotech company singularly focused on addressing the high unmet medical need in Eosinophilic Esophagitis (EoE). Its lead asset, APT-1011, is a Phase 3-stage oral therapy acquired from Adare Pharmaceuticals, positioning Ellodi as a late-stage contender in a market with no FDA-approved orally disintegrating treatment. The company is led by a seasoned team with deep GI and rare disease expertise, aiming to develop and commercialize transformative therapies for this underserved patient population.

GastroenterologyImmunology

Technology Platform

Focused on an orally disintegrating tablet (ODT) formulation for targeted topical delivery of therapy to the esophagus, specifically for Eosinophilic Esophagitis.

Opportunities

The primary opportunity is addressing the large, growing, and underserved market for Eosinophilic Esophagitis (EoE) with a convenient, first-in-class orally disintegrating tablet.

Success with APT-1011 could position Ellodi as a leader in topical EoE therapy, leading to a lucrative acquisition or partnership with a larger pharmaceutical company possessing established GI commercial capabilities.

Risk Factors

The company faces extreme binary risk as its entire value depends on the success of a single Phase 3 trial for APT-1011.

Additional key risks include intense competition from newly approved biologics and other late-stage candidates, potential regulatory hurdles, and the financial challenges of a pre-revenue biotech with a limited cash runway.

Competitive Landscape

The EoE competitive landscape is rapidly evolving. Ellodi's APT-1011 competes directly with Takeda's TAK-721 (budesonide oral suspension, Phase 3) in the topical corticosteroid space and against the first FDA-approved therapy, Sanofi/Regeneron's systemic biologic dupilumab. Other biologics and novel mechanisms are also in development, creating a crowded and competitive market for a new entrant.

More companies in Small Molecule Drugs →More companies in United States →